Atrial fibrillation and flutter in patients hospitalized for COVID-19: The challenging role of digoxin
J Cardiovasc Electrophysiol
.
2021 Mar;32(3):878-879.
doi: 10.1111/jce.14894.
Epub 2021 Feb 1.
Authors
Eftychios Siniorakis
1
,
Spyridon Arvanitakis
1
,
Antonios Katsianis
1
,
Maximilianos Elkouris
2
Affiliations
1
Department of Cardiology, Sotiria Chest Diseases Hospital, Athens, Greece.
2
Department of Clinical Biochemistry, Sotiria Chest Diseases Hospital, Athens, Greece.
PMID:
33522637
PMCID:
PMC8013483
DOI:
10.1111/jce.14894
No abstract available
Publication types
Letter
Comment
MeSH terms
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Atrial Flutter* / diagnosis
Atrial Flutter* / drug therapy
COVID-19*
Digoxin / adverse effects
Humans
SARS-CoV-2
Substances
Digoxin